Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001209 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors
A Phase 1 study of Sarcoma and Osteosarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT00001209 is a Phase 1 study of Sarcoma and Osteosarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 120 participants, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001209, a Phase 1 study of Sarcoma and Osteosarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to radiotherapy in producing complete responses and disease-free survival in patients with Ewing's sarcoma, primitive sarcoma of bone, peripheral neuroepithelioma, and soft tissue sarcoma. This will not be a randomized study but will be comparable to the large data base of similar patients treated on successive Pediatric Branch studies.
Conditions Studied
Interventions
- DRUG vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 1986-10 |
| Est. Completion | 2000-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001209
The ClinicalTrials.gov registry entry for NCT00001209 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 920-participant average among 122 other Sarcoma trials with a reported enrollment target (87% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16 is the first listed.
NCT00001209 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001209 about?
NCT00001209 is a clinical study titled "A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors". This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to radiotherapy in producing complete responses and disease-free survival ...
What is the current status of trial NCT00001209?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 1986-10. Estimated completion is 2000-08.
What conditions does trial NCT00001209 study?
This clinical trial studies the following conditions: Sarcoma, Osteosarcoma, Sarcoma, Ewing's, Neuroectodermal Tumor, Primitive, Neuroepithelioma.
What interventions are being tested in trial NCT00001209?
The interventions under investigation include: vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16 (DRUG).
Who is sponsoring clinical trial NCT00001209?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001209 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.